NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., trading under ticker BRPA, filed an 8-K current report with the SEC on March 24, 2026, continuing its public-company disclosure obligations following the completion of its SPAC business combination. The vehicle originated as Big Rock Partners Acquisition Corp, sponsored by Big Rock Partners LLC, which priced its IPO in 2019 and targeted the biopharmaceutical sector. NRX Pharmaceuticals focuses on central nervous system and pulmonary therapeutic development, with its lead programs addressing serious psychiatric and respiratory conditions. The post-merger entity remains publicly listed and subject to ongoing Exchange Act reporting requirements. Sign up for SpacDesk to access full filing history, sponsor profiles, and real-time SPAC data on BRPA and hundreds of other vehicles.